eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Royal Free London NHS Foundation Trust, through its Cell and Vector Innovation Centre (CVIC), have entered a strategic collaboration to build a seamless, scalable pathway for cell and gene therapy development and manufacturing in the UK.

The collaboration brings together CVIC's early-phase clinical manufacturing expertise with eXmoor’s later-phase clinical manufacturing capabilities and its planned progression toward a commercial manufacturing license. Together, the organisations aim to create a joined-up translational pathway that reduces complexity, accelerates timelines, and strengthens the UK’s position as a global leader in advanced therapeutics.

Linking early innovation with commercial-scale delivery

By aligning technical transfer processes, quality systems, and regulatory expertise, the collaboration will enable more efficient transitions between early and later stages of manufacturing. This will help academic, clinical, and commercial innovators navigate the journey from proof of concept through to first-in-human trials and ultimately commercial launch.

Joint areas of focus include:

• Development of harmonised technology transfer protocols, quality frameworks, and digital documentation
• Shared expertise in Qualified Person (QP) responsibilities, regulatory strategy, and quality management
• Collaborative process development, technical consultation, and regulatory problem-solving
• Staff training programmes and knowledge exchange across both organisations

By establishing a trusted model for academic-industry collaboration, the partnership aims to provide greater clarity to early-stage innovators on long-term commercial feasibility, while creating a platform to demonstrate robust UK-based manufacturing routes to both domestic and international stakeholders.

Angela Osborne, Founder & Executive Chair of eXmoor Pharma, commented:
“This collaboration is a powerful example of how the UK’s strength in early research can be matched with long-term manufacturing foresight. CVIC is doing vital work in early-phase GMP, and by connecting that with eXmoor’s development and commercialisation expertise, we can create a clearer, more supportive route to bring promising therapies to patients. It’s about strengthening the UK ecosystem so that innovation stays here and thrives here.”

Owen Bain, Director of CVIC, Royal Free London NHS Foundation Trust, said:
“For the UK’s cell and gene therapy sector to truly thrive, key learnings must flow freely across institutional and commercial boundaries. This collaboration is designed to do exactly that - connecting NHS early-phase experience with eXmoor’s development and commercial manufacturing expertise. By sharing practical know-how, aligning standards, and building mutual understanding, we can catalyse the manufacturing pathway for the next wave of innovators and create a stronger, more resilient UK ecosystem for advanced therapies.”